Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Sawicki PT, Siebenhofer A  
Beta-blockers and diabetes mellitus

Journal of Clinical and Basic Cardiology 2001; 4 (1): 17-20

PDF    Summary   

Keywords: BetablockerDiabetes mellitusHypertonieNephropathiebeta-blockerDiabetes mellitushypertensionnephropathy

Beta-blockers have been convincingly shown to reduce total and cardiovascular morbidity and mortality in hypertensive diabetic patients. After myocardial infarction these agents confer a twice as high protective effect when compared to non-diabetic patients. However, most paradoxically, beta-blocking agents are used less frequently in diabetes. A thorough analysis of the literature does not reveal adverse metabolic effects, a higher risk of hypoglycaemia or less nephroprotective effects of beta1-selective beta-blocking agents, which could justify the reticence in prescribing these antihypertensive agents to diabetic patients. The unnecessary less frequent prescription of beta1-selective beta-blockers in diabetes mellitus contributes to the higher cardiovascular mortality in these patients. J Clin Basic Cardiol 2001; 4: 17-20.
copyright © 2000–2024 Krause & Pachernegg GmbH | Sitemap | Datenschutz | Impressum